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Background
Antibodies to the V1/V2 domain of gp120 have recently
been identified as a correlate of protection in the RV144
clinical trial. To better understand the specificity of
broadly neutralizing antibodies) to the V1/V2 domain of
Thai CRF01_AE viruses, we analyzed the specificity of
antibodies in HIV+ elite neutralizer (EN) sera by swarm
analysis.
Methods
Swarm analysis makes use of the swarm of closely envel-
ope variants that evolve in each HIV-1 infected individual,
as a source of naturally occurring and biologically relevant
mutations that confer neutralization sensitivity/resistance.
Envelopes from clade B and CRF01_AE viruses were
tested for neutralization sensitivity/resistance with sera
from ENs infected with clade B and CRF01_AE viruses.
Results
We found five mutations in the V1 domain that affected
neutralization sensitivity/ resistance of CRF01_AE viruses.
This differed from clade B viruses in which mutations
altering neutralization sensitivity/resistance clustered in
the V2 domain. Structural studies have shown that the
V1/V2 domain of gp120 consists of a four-stranded b-
sheet structure. We found that mutations affecting neutra-
lization sensitivity/resistance in Thai CRF01_AE viruses
clustered around the exposed turn at the junction of the
A-B strands. In contrast, the mutations that altered neu-
tralization sensitivity/resistance in clade B viruses clus-
tered around exposed turns at the junction of the B-C and
the C-D strands.
Conclusion
The present studies suggest that there is a major difference
in the antigenic structure of the V1V2 domain between
clade B and CRF01_AE envelope proteins. These results
suggest that antibodies to the V1 domain of CRF01_AE
envelope proteins should be evaluated as a correlate of
protection in the RV144 trial. For this purpose, studies
using novel proteins and scaffolds, that replicate the struc-
ture of conformation- and glycoform- dependent epitopes
in the V1/V2 domain, are under investigation.
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